$SNSS Seven years after licensing BTK inhibitor from Biogen, beleaguered pennystock biotech partner concedes defeat endpts.com/seven-years-afte...... "The safety profile was “excellent”; it just didn’t seem to have much of an effect." Ya know, sorta like a sugar pill. Safe but not too effective. Worthless drug.
  • 1
1 Like